ORIC PHARMAC.INC.DL-0001
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor… Read more
ORIC PHARMAC.INC.DL-0001 (4TZ) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ORIC PHARMAC.INC.DL-0001 (4TZ) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ORIC PHARMAC.INC.DL-0001 - Net Assets Trend (None–None)
This chart illustrates how ORIC PHARMAC.INC.DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ORIC PHARMAC.INC.DL-0001 (None–None)
The table below shows the annual net assets of ORIC PHARMAC.INC.DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ORIC PHARMAC.INC.DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ORIC PHARMAC.INC.DL-0001 Competitors by Market Cap
The table below lists competitors of ORIC PHARMAC.INC.DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kissei Pharmaceutical Co. Ltd
PINK:KSPHF
|
$666.75 Million |
|
Motorcomm Electronic Technology Co. Ltd. A
SHG:688515
|
$666.84 Million |
|
Cofoe Medical Technology Co.Ltd.
SHE:301087
|
$666.89 Million |
|
VALNEVA SE SP.ADS/2
F:AYJ0
|
$667.13 Million |
|
HEROUX-DEV.
F:5D6
|
$666.55 Million |
|
JC Finance & Tax Interconnect Holdings Ltd
SHE:002530
|
$666.39 Million |
|
Mahanagar Gas Limited
NSE:MGL
|
$666.36 Million |
|
Sdiptech AB (publ)
PINK:SDTHF
|
$666.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ORIC PHARMAC.INC.DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ORIC PHARMAC.INC.DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ORIC PHARMAC.INC.DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ORIC PHARMAC.INC.DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ORIC PHARMAC.INC.DL-0001 (4TZ) | €- | N/A | N/A | $666.70 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |